TWD
BCRX icon

True Wealth Design’s BioCryst Pharmaceuticals BCRX Stock Holding History

True Wealth Design’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.95K Sell
354
-592
-63% -$5.58K ﹤0.01% 1539
2026
Q2 		$9.46K Buy
+946
New +$8.55K ﹤0.01% 1077
2025
Q4 		– Sell
-39
Closed -$297 – 2584
2025
Q3 		$297 Sell
39
-64
-62% -$533 ﹤0.01% 2195
2025
Q2 		$923 Sell
103
-1,145
-92% -$10.7K ﹤0.01% 1507
2025
Q1 		$9.36K Buy
1,248
+961
+335% +$7.75K ﹤0.01% 490
2024
Q4 		$2.16K Sell
287
-502
-64% -$3.81K ﹤0.01% 716
2024
Q3 		$6K Buy
+789
New +$6K ﹤0.01% 526

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
RF
RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

True Wealth Design's BCRX Position: Q3 2026 in Review

True Wealth Design reduced its BioCryst Pharmaceuticals (BCRX) stake by 63% in Q3 2026, selling an estimated $5.58K and leaving 354 shares worth $2.95K. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

True Wealth Design first reported a position in BCRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $9.46K in Q2 2026. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • True Wealth Design held 354 shares of BioCryst Pharmaceuticals worth $2.95K as of Q3 2026.
  • True Wealth Design sold 592 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $5.58K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1539 holding.
  • True Wealth Design first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • True Wealth Design's BioCryst Pharmaceuticals position peaked at $9.46K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.